PC
JAZZ icon

Parrish Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Parrish Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$767K Sell
3,182
-266
-8% -$58.3K 0.74% 64
2026
Q1 		$652K Buy
3,448
+407
+13% +$71.1K 0.58% 69
2025
Q4 		$517K Buy
+3,041
New +$466K 0.47% 74

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Parrish Capital's JAZZ Position: Q2 2026 in Review

Parrish Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 7.7% in Q2 2026, selling an estimated $58.3K and leaving 3,182 shares worth $767K. The position accounts for 0.74% of the portfolio, ranked #64.

Parrish Capital first reported a position in JAZZ in Q4 2025 and has held it in 3 quarters since. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Parrish Capital held 3,182 shares of Jazz Pharmaceuticals worth $767K as of Q2 2026.
  • Parrish Capital sold 266 Jazz Pharmaceuticals shares in Q2 2026, an estimated $58.3K.
  • Jazz Pharmaceuticals made up 0.74% of Parrish Capital's portfolio in Q2 2026, its #64 holding.
  • Parrish Capital first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Parrish Capital's 13F filing for Q2 2026, filed 1 Sep 2026.